Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS.

AIMS To evaluate the diagnostic and therapeutic procedures which were followed in a European Organization for Research and Treatment of Cancer (EORTC) randomized clinical trial investigating the role of radiotherapy in breast-conserving treatment (BCT) for ductal carcinoma in situ (DCIS) of the breast. METHODS The medical files of 824 of the 1010 randomized patients (82%) were reviewed during site visits to 30 participating institutes. RESULTS Large variations occurred, particularly in the surgical procedures and histopathological work-up which were performed. Important risk factors like tumour size and margin status were poorly quantified in the medical files. CONCLUSIONS These findings emphasize the need for establishing uniform guidelines for diagnostic and therapeutic procedures for DCIS, and for clearly defined risk factors for recurrence after BCT for DCIS. Because of its randomized nature, the main question of the trial, i.e. the effect of radiotherapy on the risk of local recurrence, will not be influenced by variation. The risk of local recurrence in itself, and hence the success of BCT for DCIS, may however be influenced by the quality of the initial procedures that were conducted.

[1]  B. Cutuli.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of protocol B‐17 , 2000, Cancer.

[2]  J. Peterse,et al.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 , 2000, The Lancet.

[3]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[4]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[5]  B. Armstrong,et al.  An audit of breast cancer pathology reporting in Australia in 1995 , 1999, British Journal of Cancer.

[6]  R. Mansel,et al.  The fourth EORTC DCIS Consensus meeting (Château Marquette, Heemskerk, The Netherlands, 23-24 January 1998)--conference report. , 1998, European journal of cancer.

[7]  D. Winchester,et al.  Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast , 1998, CA: a cancer journal for clinicians.

[8]  J. Costantino,et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Cheng,et al.  Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease. , 1997, Journal of the National Cancer Institute.

[10]  D. Wazer,et al.  The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. , 1997, International journal of radiation oncology, biology, physics.

[11]  I. Fentiman,et al.  Comparison of the surgical procedures for breast conserving treatment of early breast cancer in seven EORTC centres. , 1996, European journal of cancer.

[12]  M. Cunningham,et al.  Factors affecting outcome of patients with impalpable breast cancer detected by breast screening , 1996, The British journal of surgery.

[13]  M. Silverstein,et al.  A prognostic index for ductal carcinoma in situ of the breast , 1996, Cancer.

[14]  H. Bartelink,et al.  EORTC guidelines for writing protocols for clinical trials of radiotherapy. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Joseph Costantino,et al.  Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17. Intraductal carcinoma (ductal carcinoma in situ) , 1995, Cancer.

[16]  G. Haase.  The implications of surgical quality assurance in cancer clinical trials , 1994, Cancer.

[17]  P. Bult,et al.  Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. , 1994, Seminars in diagnostic pathology.

[18]  M. Silverstein,et al.  Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors , 1994, Cancer.

[19]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[20]  D. Schultz,et al.  Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast‐conserving surgery and definitive irradiation correlation of pathologic parameters with outcome of treatment , 1993, Cancer.

[21]  K. Zedeler,et al.  Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. , 1992, The American journal of surgical pathology.

[22]  A. Patchefsky,et al.  Subclinical ductal carcinoma in situ of the breast: Treatment by local excision and surveillance alone , 1992, Cancer.

[23]  J. Peterse,et al.  Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. , 1992, European journal of cancer.

[24]  H. Bartelink,et al.  Quality assurance of the EORTC trial 22881/10882: "assessment of the role of the booster dose in breast conserving therapy": the Dummy Run. EORTC Radiotherapy Cooperative Group. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  B. McCormick,et al.  Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. , 1991, International journal of radiation oncology, biology, physics.

[26]  J. Hendriks,et al.  Extent, distribution, and mammographic/ histological correlations of breast ductal carcinoma in situ , 1990, The Lancet.

[27]  J. Horiot,et al.  Quality assurance control in the EORTC cooperative group of radiotherapy. 3. Intercomparison in an anatomical phantom. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. Horiot,et al.  Quality assurance control in the EORTC cooperative group ofradiotherapy , 1986 .

[29]  N. Bundred,et al.  The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. , 1998, British Journal of Cancer.

[30]  J. Peterse,et al.  Third meeting of the DCIS Working Party of the EORTC (Fondazione Cini, Isola S. Giorgio, Venezia, 28 February 1994)--Conference report. , 1994, European journal of cancer.

[31]  I. Fentiman,et al.  Quality assurance of surgery in clinical trials. , 1994, European journal of cancer.

[32]  U. Chetty,et al.  Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. , 1993, Human pathology.

[33]  J. Verweij,et al.  EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials. , 1991, European journal of cancer.

[34]  J. Horiot,et al.  Quality assurance control in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  J. Horiot,et al.  Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organization for Research and Treatment of Cancer. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.